(Total Views: 343)
Posted On: 09/22/2020 2:32:33 PM
Post# of 653
They use outstanding shares as 2.38B, and the company has proposed a pathway to 6B, so that $2.83 may be a bit over optimistic. But the computation used 50% on all sales, and there are different allocations depending on location.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S. , Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
It is also based on 150K patients per month, which may be a conservative estimate, so who knows, perhaps we can hope for said $2.83
Also, no distinction is made between IV and nebulizer.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S. , Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
It is also based on 150K patients per month, which may be a conservative estimate, so who knows, perhaps we can hope for said $2.83
Also, no distinction is made between IV and nebulizer.
(1)
(0)
